Prosecution Insights
Last updated: October 25, 2026
Application No. 18/894,338

COMPOSITIONS AND METHODS FOR INHIBITING KINASES

Non-Final OA §102§112
Filed
Sep 24, 2024
Priority
Apr 23, 2015 — provisional 62/151,659 +9 more
Examiner
ORWIG, KEVIN S
Art Unit
3991
Tech Center
3900
Assignee
Inhibikase Therapeutics Inc.
OA Round
1 (Non-Final)
26%
Grant Probability
At Risk
1-2
OA Rounds
2y 1m
Est. Remaining
66%
With Interview

Examiner Intelligence

Grants only 26% of cases
26%
Career Allowance Rate
182 granted / 714 resolved
-34.5% vs TC avg
Strong +40% interview lift
Without
With
+40.1%
Interview Lift
resolved cases with interview
Typical timeline
4y 2m
Avg Prosecution
19 currently pending
Career history
732
Total Applications
across all art units

Statute-Specific Performance

§101
1.0%
-39.0% vs TC avg
§103
40.2%
+0.2% vs TC avg
§102
16.4%
-23.6% vs TC avg
§112
25.7%
-14.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 714 resolved cases

Office Action

§102 §112
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . DETAILED ACTION Status of the Claims Claims 22 is currently pending and is the subject of this Office Action. This is the first Office Action on the merits of the claims. Information Disclosure Statement The references cited on the information disclosure statement(s) were considered and have been made of record to the extent that each was provided. Claim Rejections - 35 USC § 112(b) or (pre-AIA ) 35 USC § 112 (2nd Par.) The following is a quotation of 35 U.S.C. 112(b): (B) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. Claim 22 is rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor, or for pre-AIA the applicant regards as the invention. It is not clear whether the phrases "(e.g., dimethylamino)" and "(e.g., bromo)" are limitations or whether they are merely listing disclosed examples and/or embodiments. Description of examples or preferences is properly set forth in the specification rather than the claims. Since it is unclear whether this phrase is a limitation, and thus part of the claimed invention, this phrase renders the claim indefinite. See MPEP § 2173.05(d). Priority The earliest effective US filing date afforded claim 22 has been determined to be 04/23/2015, the filing date of provisional application No. 62/151,659 to which the instant application claims priority. Claim Rejections - 35 USC § 102 The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale or otherwise available to the public before the effective filing date of the claimed invention. Claim 22 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by HUNT (US 2010/0298337; Pub. Nov. 25, 2010). Hunt teaches the use of (E)-1-(5-bromo-pyridin-3-yl)-3-dimethylamino-propenone as a starting material to make 4-(5-bromo-pyridin-3-yl)-2-pyridin-2-yl-pyrimidine ([0227]-[0228]). (E)-1-(5-bromo-pyridin-3-yl)-3-dimethylamino-propenone is encompassed by the structure of Formula (II) in claim 22 where R2 = bromo (i.e., halo) and R1 = dimethylamino. Hunt anticipates claim 22. Claim 22 is rejected under 35 U.S.C. 102(a)(1) as being anticipated by LI (US 2010/0234406; Pub. Sep. 16, 2010). Li teaches the preparation of compound 7 (i.e., 1-(5-bromo-pyridin-3-yl)-3-dimethylamino-propenone) ([0116]-[0117]). 1-(5-bromo-pyridin-3-yl)-3-dimethylamino-propenone is encompassed by the structure of Formula (II) in claim 22 where R2 = bromo (i.e., halo) and R1 = dimethylamino. Li anticipates claim 22. Conclusion Claim 22 is rejected. No claims are currently allowable. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Kevin S Orwig whose telephone number is (571)270-5869. The examiner can normally be reached Mon.-Fri. 7AM-4PM (with alternate Fridays off). If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Patricia Engle can be reached Mon.-Fri. at (571)272-6660. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of applications may be obtained from Patent Center. Patent Center is available to registered users regarding unpublished application information. To file and manage patent submissions, visit: https://patentcenter.uspto.gov and for more information visit https://www.uspto.gov/patents/apply/patent-center and https://www.uspto.gov/patents/docx. The fax number for the organization where this application is assigned is (571) 273-8300. For additional questions, contact the Electronic Business Center (EBC) at (866) 217-9197. If you would like assistance from a USPTO Customer Service Representative, call (800) 786-9199 or (571) 272-1000. /Kevin S Orwig/ Primary Examiner, Art Unit 3991
Read full office action

Prosecution Timeline

Sep 24, 2024
Application Filed
Sep 30, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent RE51085
ANTI-BCMA ANTIBODIES AND USES THEREOF
4y 5m to grant Granted Oct 20, 2026
Patent 12741987
RATIONALE, DESIGN, SYNTHESIS AND VALIDATION OF A SMALL MOLECULE ANTICANCER AGENT
3y 1m to grant Granted Sep 22, 2026
Patent RE50997
DIAGNOSTIC METHOD BASED ON LARGE SCALE IDENTIFICATION OF POST-TRANSLATIONAL MODIFICATION OF PROTEINS
2y 10m to grant Granted Aug 18, 2026
Patent RE50977
METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF
3y 4m to grant Granted Aug 04, 2026
Patent RE50916
METHODS FOR PRODUCTION OF PLATELETS FROM PLURIPOTENT STEM CELLS AND COMPOSITIONS THEREOF
3y 3m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
26%
Grant Probability
66%
With Interview (+40.1%)
4y 2m (~2y 1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 714 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month